Effect of omega-3 plus methylphenidate as an alternative therapy to reduce attention deficit-hyperactivity disorder in children |
Mohammadzadeh, Soleiman
(Child and Adolescent Psychiatrist, Neurosciences Research Center, Kurdistan University of Medical Sciences)
Baghi, Narmin (Neurosciences Research Center, Kurdistan University of Medical Sciences) Yousefi, Fayegh (Neurosciences Research Center, Kurdistan University of Medical Sciences) Yousefzamani, Bahar (Besat Hospital, Kurdistan University of Medical Sciences) |
1 | Chen JR, Hsu SF, Hsu CD, Hwang LH, Yang SC. Dietary patterns and blood fatty acid composition in children with attention-deficit hyperactivity disorder in Taiwan. J Nutr Biochem 2004;15:467-72. DOI |
2 | Rather YH, Sheikh AA, Sufi AR, Qureshi AA, Wani ZA, Shaukat TS. ADHD presenting as recurrent epistaxis: a case report. Child Adolesc Psychiatry Ment Health 2011;5:13. DOI |
3 | Banaschewski T, Roessner V, Dittmann RW, Santosh PJ, Rothenberger A. Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry 2004;13 Suppl 1:I102-16. |
4 | Barkley RA, McMurray MB, Edelbrock CS, Robbins K. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics 1990;86:184-92. |
5 | DuPaul GJ, RA Barkley, DF Connor. Stimulants. In: Barkley RA, edior. Attention deficit hyperactivity disorder: A handbook for diagnosis and treatment. 2nd ed. New York: Guilford Press; 1998. p. 510-51. |
6 | Elia J, Borcherding BG, Rapoport JL, Keysor CS. Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true nonresponders? Psychiatry Res 1991;36:141-55. DOI |
7 | Sinn N, Bryan J. Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. J Dev Behav Pediatr 2007;28:82-91. DOI |
8 | Aben A, Danckaerts M. Omega-3 and omega-6 fatty acids in the treatment of children and adolescents with ADHD. Tijdschr Psychiatr 2010;52:89-97. |
9 | Bloch MH, Qawasmi A. Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis. J Am Acad Child Adolesc Psychiatry 2011;50:991-1000. DOI |
10 | Perera H, Jeewandara KC, Seneviratne S, Guruge C. Combined and supplementation in children with attention-deficit hyperactivity disorder (ADHD) refractory to methylphenidate treatment: a doubleblind, placebo-controlled study. J Child Neurol 2012;27:747-53. DOI |
11 | Johnson M, Ostlund S, Fransson G, Kadesjo B, Gillberg C. Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: a randomized placebo-controlled trial in children and adolescents. J Atten Disord 2009;12:394-401. DOI |
12 | Antalis CJ, Stevens LJ, Campbell M, Pazdro R, Ericson K, Burgess JR. Omega-3 fatty acid status in attention-deficit/hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids 2006;75:299-308. DOI |
13 | Colter AL, Cutler C, Meckling KA. Fatty acid status and behavioural symptoms of attention deficit hyperactivity disorder in adolescents: a case-control study. Nutr J 2008 Feb 14;7:8. doi: 10.1186/1475-2891-7-8. DOI |
14 | Bazinet RP, Laye S. Polyunsaturated fatty acids and their metabolites in brain function and disease. Nat Rev Neurosci 2014;15:771-85. DOI |
15 | Chalon S. Omega-3 fatty acids and monoamine neurotransmission. Prostaglandins Leukot Essent Fatty Acids 2006;75:259-69. DOI |
16 | Zhang S, Faries DE, Vowles M, Michelson D. ADHD Rating Scale IV: psychometric properties from a multinational study as a clinicianadministered instrument. Int J Methods Psychiatr Res 2005;14:186-201. DOI |
17 | Kodas E, Galineau L, Bodard S, Vancassel S, Guilloteau D, Besnard JC, et al. Serotoninergic neurotransmission is affected by n-3 polyunsaturated fatty acids in the rat. J Neurochem 2004;89:695-702. DOI |
18 | Vancassel S, Blondeau C, Lallemand S, Cador M, Linard A, Lavialle M, et al. Hyperactivity in the rat is associated with spontaneous low level of n-3 polyunsaturated fatty acids in the frontal cortex. Behav Brain Res 2007;180:119-26. DOI |
19 | Kirley A, Hawi Z, Daly G, McCarron M, Mullins C, Millar N, et al. Dopaminergic system genes in ADHD: toward a biological hypothesis. Neuropsychopharmacology 2002;27:607-19. DOI |
20 | Carlson RV, van Ginneken NH, Pettigrew LM, Davies A, Boyd KM, Webb DJ. The three official language versions of the Declaration of Helsinki: what's lost in translation? J Med Ethics 2007;33:545-8. DOI |
21 | Hawkey E, Nigg JT. Omega-3 fatty acid and ADHD: blood level analysis and meta-analytic extension of supplementation trials. Clin Psychol Rev 2014;34:496-505. DOI |
22 | Amiri S, Farhang S, Ghoreishizadeh MA, Malek A, Mohammadzadeh S. Double-blind controlled trial of venlafaxine for treatment of adults with attention deficit/hyperactivity disorder. Hum Psychopharmacol 2012;27:76-81. DOI |
23 | Konigs A, Kiliaan AJ. Critical appraisal of omega-3 fatty acids in attention-deficit/hyperactivity disorder treatment. Neuropsychiatr Dis Treat 2016;12:1869-82. DOI |
24 | Mohammadi MR, Mohammadzadeh S, Akhondzadeh S. Memantine versus methylphenidate in children and adolescents with attention deficit hyperactivity disorder: a double-blind, randomized clinical trial. Iran J Psychiatry 2015;10:106-14. |
25 | Mohammadzadeh S, Ahangari TK, Yousefi F. The effect of memantine in adult patients with attention deficit hyperactivity disorder. Hum Psychopharmacol 2019;34:e2687. DOI |
26 | Kuperman S, Perry PJ, Gaffney GR, Lund BC, Bever-Stille KA, Arndt S, et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Ann Clin Psychiatry 2001;13:129-34. DOI |
27 | Durston S, Konrad K. Integrating genetic, psychopharmacological and neuroimaging studies: a converging methods approach to understanding the neurobiology of ADHD. Dev Rev 2007;27:374-95. DOI |
28 | Antai-Otong D, Zimmerman ML. Treatment approaches to attention deficit hyperactivity disorder. Nurs Clin North Am 2016;51:199-211. DOI |
29 | Barragan E, Breuer D, Dopfner M. Efficacy and safety of omega-3/6 fatty acids, methylphenidate, and a combined treatment in children with ADHD. J Atten Disord 2017;21:433-41. DOI |
30 | Bos DJ, Oranje B, Veerhoek ES, Van Diepen RM, Weusten JM, Demmelmair H, et al. Reduced symptoms of inattention after dietary omega-3 fatty acid supplementation in boys with and without attention deficit/hyperactivity disorder. Neuropsychopharmacology 2015;40:2298-306. DOI |
31 | Connor DF. Preschool attention deficit hyperactivity disorder: a review of prevalence, diagnosis, neurobiology, and stimulant treatment. J Dev Behav Pediatr 2002;23(1 uppl):S1-9. DOI |
32 | Rowland AS, Lesesne CA, Abramowitz AJ. The epidemiology of attention-deficit/hyperactivity disorder (ADHD): a public health view. Ment Retard Dev Disabil Res Rev 2002;8:162-70. DOI |
33 | Mick E, Biederman J, Prince J, Fischer MJ, Faraone SV. Impact of low birth weight on attention-deficit hyperactivity disorder. J Dev Behav Pediatr 2002;23:16-22. DOI |
34 | Kidd PM. Attention deficit/hyperactivity disorder (ADHD) in children: rationale for its integrative management. Altern Med Rev 2000;5:402-28. |
35 | Mick E, Biederman J, Faraone SV, Sayer J, Kleinman S. Case-control study of attention-deficit hyperactivity disorder and maternal smoking, alcohol use, and drug use during pregnancy. J Am Acad Child Adolesc Psychiatry 2002;41:378-85. DOI |